Guj. Terce Labs.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE499G01013
  • NSEID:
  • BSEID: 524314
INR
41.13
0.13 (0.32%)
BSENSE

Nov 20

BSE+NSE Vol: 52

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 890385,
    "name": "Guj. Terce Labs.",
    "stock_name": "Guj. Terce Labs.",
    "full_name": "Gujarat Terce Laboratories Ltd",
    "name_url": "stocks-analysis/guj-terce-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "41.13",
    "chg": 0.13,
    "chgp": "0.32%",
    "dir": 1,
    "prev_price": "41.00",
    "mcapval": "32.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524314,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE499G01013",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "52 ",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/guj-terce-labs-890385-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gujarat Terce Laboratories Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/gujarat-terce-laboratories-ltd-is-rated-sell-4244655",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/GujaratTerceLab_mojoScore_4244655.png",
        "date": "2026-10-30 10:10:04",
        "description": "Gujarat Terce Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Oct 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 October 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Gujarat Terce Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/gujarat-terce-laboratories-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4217027",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/GujaratTerceLab_mojoScore_4217027.png",
        "date": "2026-10-07 08:38:27",
        "description": "Gujarat Terce Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The pharmaceutical micro-cap’s recent price surge of 9.10% to ₹38.00 reflects renewed market interest, although underlying financials remain subdued. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced the rating change on 6 October 2026."
      }
    ],
    "total": 20,
    "sid": "890385",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/gujarat-terce-laboratories-890385"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "07-Nov-2026",
      "details": "Detailed disclosure is attached.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Standalone Financial Results Of The Company For The Second Quarter And Half Year Ended 30 September 2026",
      "datetime": "05-Nov-2026",
      "details": "Detailed disclosure is attached.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended From Time To Time (Listing Regulations)",
      "datetime": "05-Nov-2026",
      "details": "Detailed disclosure is attached.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

07-Nov-2026 | Source : BSE

Detailed disclosure is attached.

Unaudited Standalone Financial Results Of The Company For The Second Quarter And Half Year Ended 30 September 2026

05-Nov-2026 | Source : BSE

Detailed disclosure is attached.

Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended From Time To Time (Listing Regulations)

05-Nov-2026 | Source : BSE

Detailed disclosure is attached.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available